NPT100-18A

NPT100-18A is an αSyn oligomerization inhibitor. NPT10018A rescues cleaved caspase-3 levels to control levels. NPT10018A attenuates mitochondrial oxidative stress probe levels in a compartment-specific manner and, at higher concentrations, increases ATP signals. NPT100-18A can be used for the study of Parkinson’s disease (PD) [1][2].

Product Specifications

UNSPSC

12352005

Target

Caspase; Reactive Oxygen Species (ROS) ; α-synuclein

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB

Field of Research

Neurological Disease

Smiles

O=C1N(CC2CCNCC2)CC(N(C(CCC3=CNC4=C3C=CC=C4)=O)CCC5=O)N5C1CCCC

Molecular Formula

C28H39N5O3

Molecular Weight

493.64

References & Citations

[1]Alecu JE, et al. NPT100-18A rescues mitochondrial oxidative stress and neuronal degeneration in human iPSC-based Parkinson's model. BMC Neurosci. 2025 Jan 28;26 (1) :8.|[2]Wrasidlo W, et al. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain. 2016 Dec;139 (Pt 12) :3217-3236.